Results 51 to 60 of about 4,917 (213)

Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation

Andrology, EarlyView.
ABSTRACT Background Klinefelter syndrome is associated with a markedly increased risk of venous thrombosis. While hypogonadism and metabolic dysfunction are known contributors, the role of the contact activation system in Klinefelter syndrome remains unexplored.
Simon Chang, Claus H. Gravholt, Anne Skakkebæk, Anna‐Marie Bloch Münster, Yaseelan Palarasah   +4 more
wiley   +1 more source

Structural requirements for the procoagulant activity of nucleic acids.

PLoS ONE, 2012
Nucleic acids, especially extracellular RNA, are exposed following tissue- or vessel damage and have previously been shown to activate the intrinsic blood coagulation pathway in vitro and in vivo.
Julia Gansler, Miriam Jaax, Silke Leiting, Bettina Appel, Andreas Greinacher, Silvia Fischer, Klaus T Preissner   +6 more
doaj   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl   +5 more
wiley   +1 more source

Prekallikrein Deficiency Presenting as Recurrent Cerebrovascular Accident: Case Report and Review of the Literature

Case Reports in Hematology, 2012
We report the case of a woman with history of hypertension and hyperlipidemia presenting with recurrent episodes consistent clinically with cerebrovascular accidents (CVA), and MRI changes suggestive of ischemia versus vasculitis as their cause.
Esteban Uribe Bojanini, Arturo Loaiza-Bonilla, Agustin Pimentel   +2 more
doaj   +1 more source

A Cross-Sectional Study of KLKB1 and PRCP Polymorphisms in Patients with Cardiovascular Disease

Frontiers in Medicine, 2016
Plasma kallikrein formed from prekallikrein (PK) produces bradykinin from kininogens and activates factor XII. Plasma PK is activated by factors XIIa, XIIa or prolylcarboxypeptidase (PRCP).
Haley R. Gittleman, Alona eMerkulova, Omar eAlhalabi, Evi X. Stavrou, Martina L. Veigl, Jill S. Barnholtz-Sloan, Alvin H. Schmaier   +6 more
doaj   +1 more source

Structure?Function Studies Using Deletion Mutants Identify Domains of gC1qR/p33 as Potential Therapeutic Targets for Vascular Permeability and Inflammation [PDF]

, 2011
The endothelial cell (EC) receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1, and urokinase-type plasminogen activator receptor (uPAR) and is essential for activation of the kinin system that leads to bradykinin (BK) generation. Of these,
Berhane Ghebrehiwet, Jolyon Jesty, Sulan Xu, Rama Vinayagasundaram, Uma Vinayagasundaram, Yan Ji, Alisa Valentino, Kinga K. Hosszu, Sally Mathew, Kusumam Joseph, Allen P. Kaplan, Ellinor I. B. Peerschke   +11 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Reference materials used for specific safety evaluation of human immunoglobulin and human albumin products: features of development, certification and application

Стандартные образцы, 2019
Human immunoglobulin and human albumin products can negatively affect patients’ health. The residual content of haemagglutinins, anti-D antibodies, prekallikrein activator, as well as the level of anticomplementary activity, are controlled during both ...
O. G. Kornilova, M. A. Krivykh, R. A. Volkova, I. B. Borisevich   +3 more
doaj   +1 more source

Recombinant prolylcarboxypeptidase activates plasma prekallikrein [PDF]

Blood, 2004
AbstractThe serine protease prolylcarboxypeptidase (PRCP), isolated from human umbilical vein endothelial cells (HUVECs), is a plasma prekallikrein (PK) activator. PRCP cDNA was cloned in pMT/BIP/V5-HIS-C, transfected into Schneider insect (S2) cells, and purified from serum-free media.
Shariat‐madar, Z., Mahdi, F., Schmaier, A. H.   +2 more
openaire   +3 more sources

A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre‐Filled Pen Versus Pre‐Filled Syringe in Healthy Participants

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Garadacimab is a novel, fully human, anti‐activated factor XII monoclonal antibody approved for long‐term prophylaxis of patients with hereditary angioedema. This open‐label, parallel‐group, Phase 1, single‐center, bridging study in healthy adults (18–55 years of age) characterized the pharmacokinetics and safety of a single 200 mg ...
Fiona Glassman, John‐Philip Lawo, Mihai Alexandru Bica, Anthony Roberts, David Kormann, Ligia Chialda, Soeren Miethke, Iwona Dziadowiec, Stephen Caltabiano, Thomas Puchalski   +9 more
wiley   +1 more source